Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Pavlina Chuntova, Frances Chow, Payal B. Watchmaker, Mildred Galvez, Amy B. Heimberger, Evan W. Newell, Aaron Diaz, Ronald A. Depinho, Ming O. Li, E. John Wherry, Duane Mitchell, Masaki Terabe, Derek A. Wainwright, Jay A. Berzofsky, Christel Herold-Mende, James R. Heath, Michael Lim, Kim A. Margolin, E. Antonio Chiocca, Noriyuki KasaharaBenjamin M. Ellingson, Christine E. Brown, Yvonne Chen, Peter E. Fecci, David A. Reardon, Gavin P. Dunn, Linda M. Liau, Joseph F. Costello, Wolfgang Wick, Timothy Cloughesy, William C. Timmer, Patrick Y. Wen, Robert M. Prins*, Michael Platten, Hideho Okada

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.

Original languageEnglish (US)
Pages (from-to)356-375
Number of pages20
JournalNeuro-oncology
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2021

Keywords

  • clinical trial
  • conference report
  • glioblastoma
  • immunosuppression
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank'. Together they form a unique fingerprint.

Cite this